{"entity":{"id":"nct07639450","kind":"trial","name":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Hefei Xinzhu Biological Technology Co., Ltd., now recruiting.","summary":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07639450 by Hefei Xinzhu Biological Technology Co., Ltd., with 114 participants planned, started 2026-06-15 and due to reach its primary completion in 2028-08-31. Interventions recorded: N-3C01(Q2W), N-3C01(Q3W), N-3C01 and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07639450","url":"https://clinicaltrials.gov/study/NCT07639450"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07639450","phase":"1/2","setting":"A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination With PD-(L)1 Monoclonal Antibody in Patients With Advanced Malignant Solid Tumors","sponsor":"Hefei Xinzhu Biological Technology Co., Ltd.","enrolled":114,"outcomes":[]},"route":"/trials/nct07639450/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}